DECRYPTION – Major groups and nuggets of biotech, the entire sector is investing in innovation to score points in a rapidly growing market.
At Asco, the annual high mass of oncology in Chicago, the number of participants (42,000) and presentations (2,500) of the 2022 edition illustrate a fundamental trend: oncology continues to carry the industry pharmaceutical industry, both in terms of the number of clinical trials, companies involved and expenditure. In 2021, although the Covid pandemic weighed on consultations and therefore on treatments, the market grew by 12% to reach 185 billion dollars, according to the Iqvia institute. This represents 13.2% of total expenditure on drugs and vaccines. By 2026, it could reach 307 billion dollars (+66%). This is despite the expected arrival on the market of several biosimilars (generic versions of biological drugs).
Read alsoCancer boosts the pharmaceutical industry
“Oncology remains the largest and most dynamic market in the pharmaceutical industry, observes Jean-Marc Aubert, president of Iqvia France. This is due to the increase in the number of patients treated (+4% per year)I‘scale…
This article is for subscribers only. You have 79% left to discover.
Cultivating your freedom is cultivating your curiosity.
Keep reading your article for €0.99 for the first month
Already subscribed? Login